- Home
- OCS
as 04-18-2025 1:40pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 689.8M | IPO Year: | N/A |
| Target Price: | $30.25 | AVG Volume (30 days): | 48.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.79 - $23.08 | Next Earning Date: | 05-07-2025 |
| Revenue: | $757,024 | Revenue Growth: | -22.31% |
| Revenue Growth (this year): | 57% | Revenue Growth (next year): | 1820.89% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
GlobeNewswire
4 days ago
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
GlobeNewswire
9 days ago
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
GlobeNewswire
10 days ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GlobeNewswire
18 days ago
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
GlobeNewswire
a month ago
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
Simply Wall St.
a month ago
Lionel Carnot Spends CHF326k On Oculis Holding Stock
GlobeNewswire
a month ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.